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ABSTRACT 
 
Recently, we showed that the antiproliferative effect of ZER-NLC on Jurkat cells is 
through the apoptotic intrinsic pathway via activation of caspase-3 and -9, release of 
cytochrome c (cyt-c) from mitochondria into cytosol, and subsequent cleavage of 
polyADP-ribose polymerase (PARP). However, there has been no available 
information of ZER-NLC affects murine breast cancer cells in vivo. Thus, In this 
study, in vivo effects of ZER-NLC on murine breast cancer 4T1 cells were 
investigated. Outcomes of histopathology, immunohistochemistry and TUNEL assays 
of BALB/c mice bearing breast cancer revealed that the number of cancer cells were 
significantly decreased in mammary gland tissues after four weeks of oral 
administration of various doses of ZER-NLC. 
 
INTRODUCTION 
 
Zerumbone (ZER) is derived from several plant species of the Zingiberaceae family 
that have been investigated and recently found to possess multiple biomedical 
properties, such as anti-proliferative, antioxidant, anti-inflammatory and anticancer 
activities. ZER poor aqueous solubility has been the hindrance into creating a 
sufficient bioavailable formulation. This was resolved using nanostructured lipid 
carrier (NLC) containing ZER, prepared by hot high pressure homogenization (HPH) 
technique.  
 
MATERIALS AND METHODS 
 
Cell culture condition 
 
Murine mammary cancer cell line (4T1) was purchased from American Type Culture 
Collection (ATCC) (Maryland, USA). The cells were maintained in RPMI-1640 
(ATCC, USA) medium; supplemented with 10% heat inactivated fetal calf serum 
(FCS) (ATCC, USA), 100 units/mL penicillin, and 100 μg/mL streptomycin (Sigma 
Aldrich, USA), according to the ATCC protocol, cultured and grown in 75 cm2 
culture flasks (TPP, Switzerland) at 37˚C in an incubator with humidified atmosphere 
of 95% air and 5% CO2. 
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  Preparation of cancer cells for injection 
 
Upon growing of 4T1 cells and reaching 90% confluence, the medium was removed 
and cells washed with PBS and trypsinized. The cells were immediately centrifuged, 
washed twice with and dispersed in PBS. Trypan blue (Sigma Aldrich, USA) staining 
used to exclude dead cells. Eventually, the cells were suspended in 300 μL PBS. 
Harvested cells were used within 1 h of preparation. All animal groups excluding the 
first  group were anesthetized by an intraperitonal  injection of a mixture of ketamine-
HCl and xylazine. The remaining groups were injected intraperitonally with 4T1 cells 
(1 × 106 cells/animal) in 300 μL PBS using a tuberculin (TB) syringe and 26 G needle.  
 
Experimental design and drug treatment 
 
Group 1 comprised untreated normal healthy mice and served as the negative control 
(animals without cancer burden). Group 2 comprised of mice induced to develop 
breast cancer and served as the cancer control, while groups 3 and 4  were cancerous 
mice treated daily with 60 mg/kg body weight each with blank NLC (vehicle), and 
ZER-NLC respectively. Group 5 were treated with 4 mg/kg body weight tamoxifen 
(Sigma Aldrich, USA) , an anticancer chemotherapy drug, dissolved in distilled water 
and served as positive control. The treatments were given orally for 4 consecutive 
weeks to the animals through gastric intubations. 
 
RESULTS AND DISCUSSIONS 
 
The breast tissues of mice treated with ZER-NL displayed significant (P<0.05) and 
markedly lower numbers of neoplastic cells than those of untreated group or NLC 
group. Analysis using TUNEL assay showed that ZER-NLC, like suramine the 
anticancer drug, had anticancer activity by inducing significant (P<0.05) apoptosis of 
breast cancer cells in the mammary gland of the BALB/c mice. On the other hand, this 
study showed that oral ZER-NLC at doses of 60 mg/kg significantly (P<0.05) 
reduced expression of Bcl2 protein and increased expression of  Bax protein using 
immunohistochemistry in the breast cells compared to that of cancer control group. 
 
CONCLUSION 
 
In conclusion, the results from these characterization studies strongly suggest that 
ZER-NLCs have the potential as a probable prolonged released drug-carrier system 
useful for parenteral application in mammary gland adenocarcinoma.  
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